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Catalina Martín-Cleary1 and Jesús Egido1,2,4*Abstract
Background: Dual renin-angiotensin system blockade with angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers has been advocated to minimize proteinuria. However, recent trials have questioned
the renal safety of this approach. Our understanding on the molecular effects of dual blockade in humans is
incomplete.
Case presentation: We present a patient with corticoid resistant nephrotic syndrome who developed marked
juxtaglomerular apparatus hyperplasia and renin expression in the context of dual angiotensin system blockade.
Conclusions: Although renin may have profibrotic effects mediated by (pro)renin receptor activation, this report
raises questions on the potential consequences of local renin activation on chronic kidney disease in patients with
dual angiotensin blockade.
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Angiotensin II blockade is the mainstay of antiproteinu-
ric therapy [1,2]. Dual angiotensin system blockade with
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been advo-
cated to maximize the antiproteinuric effect [1,2]. How-
ever, the COOPERATE study was retracted and in the
ONTARGET clinical trial dual blockade was more effect-
ive in decreasing albuminuria but increased the risk of
adverse renal outcomes [3,4]. Diuretics enhance the anti-
proteinuric effect of RAS blockade with ACEi and ARBs
[5,6]. More recently, a vitamin D receptor activator
exerted a modest antiproteinuric effect as an add-on
therapy in diabetic patients with angiotensin blockade
[7]. Effective angiotensin II blockade may lead to a com-
pensatory increase in renin production and juxtaglo-
merular apparatus hyperplasia in animal models, but* Correspondence: jegido@fjd.es
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distribution, and reproduction in any mediumthere is little information in humans [8]. Calcineurin
inhibitors have also been associated with juxtaglomeru-
lar apparatus hyperplasia attributed to chronic renal is-
chemia [9,10]. We present a persistently proteinuric
patient who developed a remarkable juxtaglomerular ap-
paratus hyperplasia in the course of dual angiotensin
blockade for proteinuria. This case illustrates the limita-
tions of currently available antiproteinuric approaches as
well as the occurrence of physiological responses to
therapy of unclear clinical significance.Case presentation
A 22-year-old male was referred to our hospital because
of nephrotic syndrome. At age 17, in 2005, he was diag-
nosed of cranial cavernous sinus in the context of neph-
rotic syndrome. He was homozygous for the C677T
polymorphism of the methylene tetrahydrofolate reduc-
tase (MTHFR) gene and had circulating lupus anticoagu-
lant, being treated with acenocumarol, vitamin B6 and
vitamin B12.
At diagnosis, blood pressure was 140/85 mmHg,
serum creatinine (sCr) 1.6 mg/dl, proteinuria 8 g/day,ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(24 hour urine collection), 25OH Vitamin D 11.2 ng/ml
(normal 20–50) and calcitriol 21.7 pg/ml (normal 25–
65). The genetic study was negative for podocin and
nephrin gene mutations. The first renal biopsy per-
formed in January 2006 showed focal segmental glomer-
ulosclerosis, foci of tubular atrophy, mild interstitial
inflammation and fibrosis, normal arterioles and small
vessels and faint focal mesangial IgM deposits by im-
munofluorescence, with no abnormalities in juxtaglo-
merular apparatus morphology.
He was treated with prednisone (starting at 1 mg/
kg/day with slow taper) and mycophenolate mofetil
(1-2 g/day) for two years. Nephrotic syndrome per-
sisted (Figure 1.A). A short course of iv methylpredni-
solone (total dose 1250 mg) was followed by partial
remission. Tacrolimus (1 mg/bd) was prescribed for
26 months and two cycles of Rituximab (700 mg per
cycle) were added, the second of which was also fol-
lowed by partial remission. Hypertension was initially
treated with dual blockade (valsartan 160 mg/day plus
quinapril 10 mg/day for three years, and then cande-
sartan/hydrochlorotiazide 16 mg/12.5 mg plus quina-
pril 10 mg/day for two years) with ideal blood
pressure control (120-124/70-74 mmHg). Very low
levels of serum calcium, even with clinical symptoms,
and vitamin D deficiency were treated with calcium
and calcitriol 2.5 μg/week but not with native vitamin
D. In June 2009, calcitriol was replaced by 25-
hydroxy-vitamin D3 (2000 units/week) plus paricalcitol
(1–2 μg/day). Complete remission was not achieved.
In May 2010 a second renal biopsy was performed,
containing 13 glomeruli: 4 with periglomerular fibrosis
and partial retraction of the glomerular tuft, 3 scler-
osed and 2 glomeruli with focal segmental lesions. A
remarkable juxtaglomerular apparatus hyperplasia was
observed in 4 glomeruli. (Figure 1.B). Interstitial fibro-
sis was present. Immunohistochemistry revealed gran-
ules inside the juxtaglomerular apparatus with intense
renin staining (Figure 1.C). Unfortunately, plasma
renin activity and serum and urine aldosterone levels
at the time of biopsy were not available.
Discussion and conclusions
The juxtaglomerular apparatus is located in the vascular
pole of the glomerulus. Its main functions are the secre-
tion of renin and direct control of glomerular haemo-
dynamics via tubuloglomerular feedback. Renin-
containing cells are differentiated afferent arteriole cells
which contain (pro)renin packed into protogranules.
Some granules will be secreted via the constitutive path-
way releasing (pro)renin, others will be combined to
form dense core vesicles that will convert (pro)renin into
active renin. Renin release is the rate-limiting step of therenin-angiotensin system activation. Potential causes of
juxtaglomerular apparatus hyperplasia include condi-
tions that chronically stimulate renin production:
 Bartter and Gitelman syndromes
 Insulin-dependent diabetes mellitus with
microalbuminuria
 Chronic renal ischemia
 Hypertrophy of the arterial and arteriolar walls
 Chronic volume depletion
 Chronic calcineurin inhibitor treatment, especially if
nephrotoxicity is present
 ACEIs or ARBs
Most reports of juxtaglomerular apparatus hyperplasia
correspond to patients with Bartter or Gitelman syn-
dromes. Juxtaglomerular apparatus hyperplasia was also
described in a female with chronic hypotension [11].
Mild enlargement of the juxtaglomerular apparatus has
been reported in insulin-dependent diabetes mellitus
patients with microalbuminuria [12]. Among iatrogenic
causes we find chronic volume depletion following treat-
ment with diuretics, chronic calcineurin inhibitor tox-
icity and treatment with ACEIs or ARBs [8,10,12].
In experimental animals prolonged treatment with
toxic doses of cyclosporin A leads to interstitial fibrosis
and tubular atrophy with mild hyperplasia of the juxta-
glomerular apparatus that has been attributed to ische-
mia [12]. A non-significant trend towards an increased
prevalence of juxtaglomerular apparatus hyperplasia was
recently reported in patients with evidence of calcineurin
inhibitor toxicity when compared to patients on calci-
neurin inhibitors without evidence of toxicity, although
no information on angiotensin targeting therapy was
provided [10]. Thus, it is unlikely that tacrolimus, which
was stopped 26 months before the renal biopsy, was a
main contributor to juxtaglomerular apparatus hyperpla-
sia in this patient.
In animal models, ACEIs can modestly increase the
juxtaglomerular apparatus size [8]. Less information is
available in human subjects. Severe renal lesions, includ-
ing juxtaglomerular apparatus hyperplasia and intense
renin staining were present in twins from a pregnant
woman treated with ARB (losartan) during pregnancy
[13]. In our patient double angiotensin II blockade and
diuretics might have contributed to the marked juxtaglo-
merular apparatus hyperplasia. In this regard, an effect-
ive angiotensin II blockade may be expected to increase
compensatory renin production. In the past this might
have been considered of scarce clinical relevance, given
that the renin-angiotensin system was blocked down-
stream. However, current clinical evidence for potential
adverse effects on renal function of dual angiotensin
blockade [4] raise questions as to the potential molecular
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Figure 1 Clinical course and renal biopsy findings. A) Time-course of urinary protein/creatinine ratio (UPCR) and creatinine clearance (CrCl).
Renal biopsies and prescribed therapies are indicated. B) Juxtaglomerular apparatus hyperplasia, PAS staining. C) Renin immunohistochemistry.
Original magnification x200. The arrow indicates the juxtaglomerular apparatus.
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have direct profibrotic effects through activation of the
(pro)renin receptor, raising concerns as to the conse-
quences of juxtaglomerular apparatus hyperplasia [14].
Thus, activation of the (pro)renin receptor may promote
angiotensin-independent intracellular signaling and se-
cretion of the fibrogenic cytokine TGFβ1 [14]. Indeed a
(pro)renin receptor blocker prevents diabetic nephropa-
thy and cardiac fibrosis [14]. Following the renal biopsy
dual angiotensin blockade was stopped and the renin-in-
hibitor aliskiren introduced in our patient. There is evi-
dence that the magnitude of interstitial fibrosis may beattenuated to a greater degree by aliskiren than by an
ACEIs, at least in experimental diabetic nephropathy
[15]. Blood pressure was also under control but protein-
uria remained unmodified. Persistent proteinuria may
have contributed to the development of interstitial fibro-
sis (mean value during follow-up: 5.7 g/g creatinine).
Neither direct renin inhibitors nor drugs targeting al-
dosterone were used in this patient. However, the patient
received paricalcitol at a dose that was recently reported
to have additive antiproteinuric effects over ACEIs or
ARBs in diabetic nephropathy [7]. Our understanding of
the molecular mechanisms of kidney injury relies heavily
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ample evidence for the beneficial effect of vitamin D re-
ceptor activation in experimental kidney injury [16-19].
Based on these experimental data it was hypothesized
that paricalcitol inhibition of renin transcription was a
key feature of its renoprotective effect [16-19]. However,
no differences in plasma renin activity were observed be-
tween paricalcitol- and placebo-treated patients in the
VITAL study [7]. Our observation of juxtaglomerular
apparatus hyperplasia and increased renin immunoreac-
tivity despite years of full dose paricalcitol associated
with 25OH vitamin D supplementation also argue
against a key effect of vitamin D receptor activation on
renin in humans. This does not preclude alternative
mechanisms of a beneficial effect on paricalcitol on kid-
ney injury, such as direct inhibition of the podocyte re-
lease of TGFβ1 and synthesis of extracellular matrix
proteins [20] or an antiinflammatory effect independent
of modulation of proteinuria [21].
In summary we observed a remarkable juxtaglomeru-
lar apparatus hyperplasia and increased renin expression
in a focal segmental glomerulosclerosis patient on long
term treatment with different immunosuppressive
regimes, diuretics, and dual blockade with ACEI and
ARB. However neither renin direct inhibitors nor aldos-
terone inhibitor agents were used. We hypothesize that
despite vitamin D receptor activators, this therapeutic
combination chronically stimulated the juxtaglomerular
apparatus. This observation raises questions about a) po-
tential adverse consequences of the current approaches
to treat proteinuria through activation of compensatory
mechanisms that have the potential to be injurious
themselves and b) on the extrapolation of data on vita-
min D regulation of renin obtained in experimental ani-
mals to humans.
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